Russia’s cancer vaccine achieves 100pc efficacy in trials

Agency :

Russia has announced progress on a new mRNA cancer vaccine called EnteroMix. The vaccine has shown strong results in early testing, shrinking tumors and slowing growth in patients.

It was developed by the Russian Federal Medical and Biological Agency with support from leading research institutes.

The news was shared during international forums in 2025, where Russian officials said the vaccine could be ready for wider use soon.

Early trials involved 48 patients and focused on colorectal cancer. Versions for melanoma and brain cancer are also being developed.

EnteroMix is based on mRNA technology, the same platform used for COVID-19 vaccines.

Instead of using weakened viruses, it carries genetic instructions that teach the body to fight cancer.

According to Russian health officials, the vaccine is safe for repeated use and can be personalized for each patient.

Researchers explained that the vaccine uses a mix of harmless viruses to trigger the immune system.

It targets cancer cells directly and avoids the heavy side effects often linked with chemotherapy.